Compare KBH & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | VERA |
|---|---|---|
| Founded | 1957 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 1994 | 2021 |
| Metric | KBH | VERA |
|---|---|---|
| Price | $49.17 | $35.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $56.17 | ★ $81.30 |
| AVG Volume (30 Days) | 720.3K | ★ 1.8M |
| Earning Date | 03-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $4,547,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.23 | $472.48 |
| P/E Ratio | $51.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.03 | $22.72 |
| 52 Week High | $68.41 | $56.05 |
| Indicator | KBH | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 28.59 | 46.52 |
| Support Level | $44.03 | $29.66 |
| Resistance Level | $58.83 | $37.13 |
| Average True Range (ATR) | 1.49 | 1.70 |
| MACD | -0.67 | 0.12 |
| Stochastic Oscillator | 2.64 | 38.42 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.